ISCI, Volume 19

# **Supplemental Information**

# **Pim1 Impacts Enterovirus A71 Replication**

# and Represents a Potential Target

in Antiviral Therapy

Fanghang Zhou, Qianya Wan, Jing Lu, Ying Chen, Gui Lu, and Ming-Liang He

#### **1** Supplemental Figures



2

3 Figure S1. Cell viability with inhibitor treatment in different cells (related to Figure 5)

(A) We tested all Pim1 inhibitors (SGI-1776, CX-6258 and AZD-1208) for their effect on cell proliferation in
293T cell lines. Cells were incubated with the indicated concentrations for 48h. The cell viabilities were
determined by MTT assay. (B). A similar experiment to that seen in panel A was performed on RD cells. (C)
A similar experiment to that seen in panel A was performed on HeLa cells. Results are represented as mean ±
SD from three independent experiments.

9

#### 10 Transparent Methods

#### 11 **1. Viruses and cells**

RD cells (ATCC number CCL-136), HeLa cells and 293T cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) with 100 U/ml penicillin and 100 µg/ml streptomycin. EV-A71 (SHZH98 strain, GenBank accession number AF302996) was obtained from Shenzhen Center for Disease Control and Prevention, Shenzhen, China. The virus was propagated as previously described (Lu et al., 2011; Yi et al., 2011).

17

#### 18 **2. Real-Time Polymerase Chain Reaction**

19 RT-qPCR assays was used a total 1 µg RNA extracted from RD, HeLa or 293T cells. RT-qPCR assay 20 was used ImProm-II<sup>™</sup> Reverse Transcription System (Promega, USA). Real-time PCR was carried 21 out in the ABI 7500 Real-Time PCR system with Power SYBR Green Master Mix (Applied 22 Biosystems, USA), using the following program: 50°C for 2 min, 95°C for 10 min followed by 45 cycles of 95°C for 15s and 60°C for 1 min. Sets of primers for these genes are available upon request. 23 All samples were run in triplicate and the experiment was repeated three times. The messenger RNA 24 (mRNA) level of each target gene was normalized to the mRNA copies of GAPDH in the same 25 26 sample and results were expressed as a percentage of the negative control (set as 1).

27

## 28 **3. RNA interference**

29 RNA interference was carried out using siRNA purchased from Genepharma (ShangHai, China). Two 30 the Pim1 mRNA (siPim1-1-Sense: separate siRNAs corresponding to 31 AACCUUCGAAGAAAUCCAGAACCAU, siPim1-1-Antisense: 32 AUGGUUCUGGAUUUCUUCGAAGGUU; siPim1-2-Sense: 33 GUAUGAUAUGGUGUGUGGAGAUAUUC, siPim1-2-Antisense: 34 GAAUAUCUCCACACACCAUAUCAUAC) were used at 40nM to inhibit endogenous Pim1 expression. For the rescue assay (Fig. 3G&3H), siRNA was designed by targeting Pim1 3'-UTR 35 (sense: 5'-ACAUUUACAACUCAUUCCA-3', antisense: 5'-UGGAAUGAGUUGUAAAUGU-3') 36

37 (Park et al., 2015). Scramble siRNA was used as the control purchased from GenePharma (Shanghai,
38 China). Transfection of siRNA was performed according to the manufacturer's instructions. In brief,
39 cells at 50% confluence were transfected with 40 nM siRNA using Lipofectamine 3000.

40

### 41 **4. Plasmids construction**

42 Human Pim1 (Accession NM\_001243186) was amplified using Platinum Taq DNA Polymerase high

43 fidelity (Invitrogen, USA). The PCR product was cloned into pcDNA4/HisMax B (Invitrogen, USA)

vector between BamH I and Xba I sites. The EV-A71 report plasmid pRIRESF was constructed as 44 45 follows: Renilla Luciferase gene (RLuc) was inserted into pcDNA4/HisMax B between BamH I and EcoR V sites (Wang M et al., 2016); EV-A71 IRES was amplified from EV-A71 virus strain 46 47 (SHZH98). Also, Firefly Luciferase gene (FLuc) was amplified by using a primer which has an 48 overlapping sequence with the C-terminal of EV-A71 IRES. Finally, the IRES-FLuc constructs were 49 then amplified by using overlap PCR and inserted downstream of the Renilla Luciferase gene by 50 using EcoRV and XbarI. The control plasmid pRF was constructed in similar way except it contained 51 EV-A71 IRES upstream of the FLuc gene (Fig. 4A). The FLuc gene was amplified and then inserted 52 downstream of the Renilla Luciferase gene by using EcoRV and XbarI. All primers used in plasmid 53 construction are available upon request.

54

### 55 **5. Western blotting**

56 Cells were lysed in Nonidet-P40 (NP-40) buffer (150 mM sodium chloride, 1.0% NP-40, 50 mM Tris, pH 8.0, 1×Roche protease inhibitor cocktail) with occasional vortex. The cell lysates were then 57 centrifuged to remove debris at 14,000 rpm for 20 min at 4°C. The concentration of proteins in the 58 59 lysates was determined by the Bradford assay (Bio-Rad). Equal amounts of total protein for each 60 sample were loaded and separated by 8%-12% SDS-PAGE and then transferred onto polyvinylidene 61 difluoride (PVDF) membranes (Amersham Biosciences). Membranes were blocked with 5% bovine 62 serum albumin (BSA) in TBST (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) for 1 h 63 and incubated with the following specific antibodies: Pim1 (2907, CST), EV71 VP1 (MAB1255-M05, Abnova), eIF4G (sc-373892, Santa Cruz), AUF1 (ab50692, Abcam), Sam68 (ab26803, 64 65 Abcam), hnRNPK (ab18195, Abcam), FUBP1 (sc-271241, Santa Cruz). Beta-actin (sc-517582, Santa 66 Cruz) or GAPDH (sc-47724, Santa Cruz) served as the loading control. Target proteins were detected 67 with corresponding secondary antibodies (Santa Cruz Biotechnology, USA) and visualized with a C600 western blot imaging system from Azure Biosystems. Each immunoblot assay was carried out 68 69 at least three times.

70

## 71 6. Viral RNA quantification

EV-A71 viral RNA was determined as previously described (Lu et al., 2011). Briefly, the total cellular 72 73 RNA was isolated for intracellular viral RNA quantification. To calculate the extracellular virions, 74 the culture media of infected cells was firstly harvested and briefly centrifuged to remove cell debris. 75 Viral core particles were then precipitated with 10% polyethylene glycol 8000 containing 0.5 M NaCl at 4°C overnight. After centrifuging for 30 min at 16,000 g, viral particles were pelleted and treated 76 77 with 100 µg/ml of RNase A (Sigma, USA). To isolate the intracellular virions, EV-A71 infected cells 78 were lysed with lysis buffer (1% Triton 100 and 1 x Roche protease inhibitor cocktail in PBS). Then 79 the cell lysates were used to isolate viral particles as described above. To set up the standard curve of 80 infectious viruses, the viral titers were first determined by a CPE assay. Then the viral RNA was 81 extracted from the infectious EV-A71 viruses. RNA was serial diluted at tenfold and used to reflect 82 the calculated PFU from 10 to  $1 \times 10^7$  live virions.

83

## 84 **7. Virus titration.**

Virus titration was performed as reported in our previously manuscripts (Lu et al., 2012; Wang et al.,
2016). RD cells were seeded into 96-well plates for 24 h before infection, then cells were infected by
100 µl per well of serial 10-fold diluted supernatant in quintuplicate. The 50 % tissue culture-infected
dose (TCID50) was calculated by the Reed-Muench method after 96 h of infection.

89

### 90 8. Luciferase assays

91 Luciferase assays were performed as previously described (Dan et al., 2019; Dong et al., 2018). 293T 92 cells were plated in 24-wells one day before transfection. Over expression of the Pim1 plasmid or 93 corresponding siRNA were transfected. Next, 24 hours later, cells were transfected with PRIF or PRF 94 reporter plasmids. Two days after first-round transfection, cell extracts were prepared in passive 95 buffer (Promega, USA) and assayed for Renilla luciferase (RLuc) and Firefly luciferase (FLuc) 96 activity in a Lumat LB9507 bioluminometer using a dual-luciferase reporter assay (Promega)
97 according to the manufacturer's instructions.

98

## 99 9. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay

Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)
assay. After RD cells were grown in 96-well plates and treated with Pim1 inhibitors, 20 µl of MTT
(5 mg/ml) was added to each well, and cells were further incubated for an additional 4 h at 37 °C.
Next, the medium was carefully removed and subsequently 100 µl of Dimethyl Sulfoxide was added.
The optical density was measured at a wavelength of 570 nm.

105

# 106 **10. Isolation of nuclear and cytoplasmic protein**

Briefly, cells (5 to 10 x 10<sup>6</sup> cells) were collected and washed by PBS three times. Then the cytoplasm
proteins were extracted by cytoplasmic extract (CE) buffer (HEPES 10 mM, pH 7.9, KCl 10 mM,
EDTA 0.1 mM, NP-40 0.3% (added just before use), protease inhibitors 1x (added just before use)).
Subsequently, we used a nuclear extract (NE) buffer (HEPES 20 mM, pH 7.9, NaCl 0.4 M, EDTA 1
mM, Glycerol 25%, Protease Inhibitors 1x (added just before use)) to extract nuclear proteins.

112

## 113 **11. Fluorescence microscopy**

114 Fluorescence microscopy was performed on RD cells. RD cells grown on glass cover slips were pretreated with Pim1 inhibitor CX-6258. The culture media were removed, and cells were washed 115 116 three times with PBS. The cells on the coverslip were fixed with 3.7% (wt/vol) formaldehyde at room 117 temperature for 20 min. After being washed three times with PBS, cells on the coverslip were 118 permeabilized with 0.5% Triton X-100 at room temperature for 5 min and washed again three times 119 with PBS. For AUF1 immunostaining, the samples were blocked in solution (PBS, containing 5%) 120 bovine serum albumin [BSA]) for 60 min at room temperature and then incubated with anti-AUF1 121 (ab50692, San Francisco) for 1.5 h at room temperature and washed three times with PBS. The

samples were then reacted with rhodamine (tetramethyl rhodamine isothiocyanate [TRITC])conjugated goat anti-rat IgG (Jackson ImmunoResearch Laboratories, Inc.) for 1 hour at room temperature. After being washed with PBS, the samples were treated with DAPI for 5 min at room temperature and washed again with PBS three times. Finally, coverslips with adhered cells were placed on a glass slide and sealed with transparent nail polish. Images were captured by confocal laser scanning microscopy (ZEISS LSM 880 Confocal Microscope) (Lin et al., 2014).

128

# 129 **12. Statistical analysis**

130 Results were expressed as mean ± standard deviation (SD). All statistical analyses were carried out

131 with SPSS, version 16.0 software (SPSS Inc.). A two-tailed Student's T test was applied for two

132 group comparisons. A p value <0.05 was considered statistically significant.

133

#### 134 **References**

- 135 DAN, X., WAN, Q., YI, L., LU, J., JIAO, Y., LI, H., SONG, D., CHEN, Y., XU, H. & HE, M. L.
- 136 2019. Hsp27 Responds to and Facilitates Enterovirus A71 Replication by Enhancing Viral Internal
- 137 Ribosome Entry Site-Mediated Translation. J Virol, 93.
- 138 DONG, Q., MEN, R., DAN, X., CHEN, Y., LI, H., CHEN, G., ZEE, B., WANG, M. H. T. & HE,
- 139 M. L. 2018. Hsc70 regulates the IRES activity and serves as an antiviral target of enterovirus A71
- 140 infection. Antiviral Res, 150, 39-46.
- 141 LIN, J. Y., LI, M. L. & BREWER, G. 2014. mRNA decay factor AUF1 binds the internal ribosomal
- 142 entry site of enterovirus 71 and inhibits virus replication. *PLoS One*, 9, e103827.
- 143 LU, J., HE, Y. Q., YI, L. N., ZAN, H., KUNG, H. F. & HE, M. L. 2011. Viral kinetics of
- 144 enterovirus 71 in human abdomyosarcoma cells. *World J Gastroenterol*, 17, 4135-42.
- 145 LU, J., YI, L., ZHAO, J., YU, J., CHEN, Y., LIN, M. C., KUNG, H. F. & HE, M. L. 2012.
- Enterovirus 71 disrupts interferon signaling by reducing the level of interferon receptor 1. *J Virol*,
  86, 3767-76.
- 148 PARK, C., MIN, S., PARK, E. M., LIM, Y. S., KANG, S., SUZUKI, T., SHIN, E. C. & HWANG,
- 149 S. B. 2015. Pim Kinase Interacts with Nonstructural 5A Protein and Regulates Hepatitis C Virus
- 150 Entry. J Virol, 89, 10073-86.
- 151 WANG, M., DONG, Q., WANG, H., HE, Y., CHEN, Y., ZHANG, H., WU, R., CHEN, X., ZHOU,
- 152 B., HE, J., KUNG, H. F., HUANG, C., WEI, Y., HUANG, J. D., XU, H. & HE, M. L. 2016.
- 153 Oblongifolin M, an active compound isolated from a Chinese medical herb Garcinia oblongifolia,
- potently inhibits enterovirus 71 reproduction through downregulation of ERp57. Oncotarget, 7,
- 155 8797-808.
- 156 YI, L., LU, J., KUNG, H. F. & HE, M. L. 2011. The virology and developments toward control of
- 157 human enterovirus 71. Crit Rev Microbiol, 37, 313-27.
- 158